Information:
Fel:
ID
34324
Beskrivning
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience; ODM derived from: https://clinicaltrials.gov/show/NCT02485262
Länk
https://clinicaltrials.gov/show/NCT02485262
Nyckelord
Versioner (1)
- 2019-01-16 2019-01-16 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatitis C NCT02485262
Eligibility Hepatitis C NCT02485262
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C NCT02485262
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
adult chronic hcv patients aged >18
boolean
ID.2
Item
treatment naïve
boolean
ID.3
Item
patient with cirrhosis and no cirrhosis. cirrhosis defined as stage 4 fibrosis on liver biopsy or fibro sure results indicating cirrhosis or has clinical findings suggestive of cirrhosis
boolean
ID.4
Item
patients meet the indication to receive one of the sof treatment based regimens
boolean
ID.5
Item
co-infected patients with hiv or hepatitis b
boolean
ID.6
Item
patient received one of the daas regimens
boolean
ID.7
Item
patient with active substance abuse and alcohol abuse
boolean
ID.8
Item
patient received prior daa regimen
boolean
ID.9
Item
decompensated cirrhotic patients
boolean
ID.10
Item
patient has contraindication to receive sof
boolean